Literature DB >> 22244758

Structure of the Yersinia pestis FabV enoyl-ACP reductase and its interaction with two 2-pyridone inhibitors.

Maria W Hirschbeck1, Jochen Kuper, Hao Lu, Nina Liu, Carla Neckles, Sonam Shah, Steffen Wagner, Christoph A Sotriffer, Peter J Tonge, Caroline Kisker.   

Abstract

The recently discovered FabV enoyl-ACP reductase, which catalyzes the last step of the bacterial fatty acid biosynthesis (FAS-II) pathway, is a promising but unexploited drug target against the reemerging pathogen Yersinia pestis. The structure of Y. pestis FabV in complex with its cofactor reveals that the enzyme features the common architecture of the short-chain dehydrogenase reductase superfamily, but contains additional structural elements that are mostly folded around the usually flexible substrate-binding loop, thereby stabilizing it in a very tight conformation that seals the active site. The structures of FabV in complex with NADH and two newly developed 2-pyridone inhibitors provide insights for the development of new lead compounds, and suggest a mechanism by which the substrate-binding loop opens to admit the inhibitor, a motion that could also be coupled to the interaction of FabV with the acyl-carrier protein substrate.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244758      PMCID: PMC3361726          DOI: 10.1016/j.str.2011.07.019

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  59 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  Human plague in 2002 and 2003.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2004-08-13

Review 3.  Resistance of Yersinia pestis to antimicrobial agents.

Authors:  Marc Galimand; Elisabeth Carniel; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

4.  In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.

Authors:  Jong Hwa Yum; Chang Ki Kim; Dongeun Yong; Kyungwon Lee; Yunsop Chong; Cheol Min Kim; Jeong Mi Kim; Seonggu Ro; Joong Myung Cho
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

5.  Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate.

Authors:  D A Rozwarski; C Vilchèze; M Sugantino; R Bittman; J C Sacchettini
Journal:  J Biol Chem       Date:  1999-05-28       Impact factor: 5.157

6.  Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.

Authors:  Christopher W am Ende; Susan E Knudson; Nina Liu; James Childs; Todd J Sullivan; Melissa Boyne; Hua Xu; Yelizaveta Gegina; Dennis L Knudson; Francis Johnson; Charles A Peloquin; Richard A Slayden; Peter J Tonge
Journal:  Bioorg Med Chem Lett       Date:  2008-04-18       Impact factor: 2.823

Review 7.  The application of computational methods to explore the diversity and structure of bacterial fatty acid synthase.

Authors:  Yong-Mei Zhang; Hedia Marrakchi; Stephen W White; Charles O Rock
Journal:  J Lipid Res       Date:  2003-01       Impact factor: 5.922

8.  Key residues responsible for acyl carrier protein and beta-ketoacyl-acyl carrier protein reductase (FabG) interaction.

Authors:  Yong-Mei Zhang; Bainan Wu; Jie Zheng; Charles O Rock
Journal:  J Biol Chem       Date:  2003-10-03       Impact factor: 5.157

9.  CAVER: a new tool to explore routes from protein clefts, pockets and cavities.

Authors:  Martin Petrek; Michal Otyepka; Pavel Banás; Pavlína Kosinová; Jaroslav Koca; Jirí Damborský
Journal:  BMC Bioinformatics       Date:  2006-06-22       Impact factor: 3.169

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  8 in total

1.  Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes.

Authors:  Jiangwei Yao; Megan E Ericson; Matthew W Frank; Charles O Rock
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

2.  The genome of a Bacteroidetes inhabitant of the human gut encodes a structurally distinct enoyl-acyl carrier protein reductase (FabI).

Authors:  Christopher D Radka; Matthew W Frank; Jiangwei Yao; Jayaraman Seetharaman; Darcie J Miller; Charles O Rock
Journal:  J Biol Chem       Date:  2020-04-21       Impact factor: 5.157

Review 3.  Bacterial Enoyl-Reductases: The Ever-Growing List of Fabs, Their Mechanisms and Inhibition.

Authors:  Fernanda S M Hopf; Candida D Roth; Eduardo V de Souza; Luiza Galina; Alexia M Czeczot; Pablo Machado; Luiz A Basso; Cristiano V Bizarro
Journal:  Front Microbiol       Date:  2022-06-16       Impact factor: 6.064

4.  Synthesis and Antimicrobial Activity Screening of Piperazines Bearing N,N'-Bis(1,3,4-thiadiazole) Moiety as Probable Enoyl-ACP Reductase Inhibitors.

Authors:  Alaa Z Omar; Najla A Alshaye; Tawfik M Mosa; Samir K El-Sadany; Ezzat A Hamed; Mohamed A El-Atawy
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

Review 5.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

6.  Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.

Authors:  Carla Neckles; Annica Pschibul; Cheng-Tsung Lai; Maria Hirschbeck; Jochen Kuper; Shabnam Davoodi; Junjie Zou; Nina Liu; Pan Pan; Sonam Shah; Fereidoon Daryaee; Gopal R Bommineni; Cristina Lai; Carlos Simmerling; Caroline Kisker; Peter J Tonge
Journal:  Biochemistry       Date:  2016-05-17       Impact factor: 3.162

Review 7.  Bacterial lipids: metabolism and membrane homeostasis.

Authors:  Joshua B Parsons; Charles O Rock
Journal:  Prog Lipid Res       Date:  2013-03-14       Impact factor: 16.195

8.  The Synthesis of Molecular Docking Studies, In Vitro Antimicrobial and Antifungal Activities of Novel Dipeptide Derivatives Based on N-(2-(2-Hydrazinyl-2-oxoethylamino)-2-oxoethyl)-nicotinamide.

Authors:  Gaber Moustafa; Hemat Khalaf; Ahmed Naglah; Asma Al-Wasidi; Nawal Al-Jafshar; Hassan Awad
Journal:  Molecules       Date:  2018-03-27       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.